Stock comparison
Haemonetics
Perrigo
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
PRGO
Perrigo
Market cap
$1.55B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | PRGO | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 32F | HAE |
| Benjamin Graham | 85A | 32F | HAE |
| Philip Fisher | 60C | 20F | HAE |
| Peter Lynch | 54C | 16F | HAE |
| Joel Greenblatt | 31F | 19F | HAE |
| Charlie Munger | 54D | 23F | HAE |
| Terry Smith | 55D | 14F | HAE |
Side-by-side metrics
| Metric | HAE | PRGO |
|---|---|---|
| Market cap | $2.98B | $1.55B |
| P/E (TTM) | 24.8x | - |
| EV/EBIT | 14.1x | 14.5x |
| ROIC (TTM) | 8.37% | 3.37% |
| Gross margin | 55.74% | 34.17% |
| Net margin | 7.29% | -43.5% |
| Revenue CAGR 5y | 7.65% | 0.68% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 1.5x |
| Dividend yield | 0.0% | 10.43% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Net margin7.29%vs -43.5%+117%
- Revenue CAGR 5y7.65%vs 0.68%+91%
- ROIC (TTM)8.37%vs 3.37%+60%
- Market cap$2.98Bvs $1.55B+48%
PRGO leads on
- P/E (TTM)-vs 24.8x+103%
- Dividend yield10.43%vs 0.0%+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.